ArticleFrontiers in cellular and infection microbiology2018
Evaluating New Compounds to Treat
Article in Frontiers in cellular and infection microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Discovery of repurposed drugs that disrupt intracellular replication of Burkholderia pseudomallei and Burkholderia mallei and protect against lethal aerosol infection.PLoS pathogens · 2026Article
- Phage-mediated control of melioidosis in Southern China: molecular insights and therapeutic potential of N4-like viruses from Hainan.BMC microbiology · 2025Article
- New Frontiers for Old Medications: Repurposing Approved Drugs Against Gram-Negative Bacterial Infections.Microorganisms · 2025Review
- Review
- The Many Lives of Auranofin: How an Old Anti-Rheumatic Agent May Become a Promising Antimicrobial Drug.Antibiotics (Basel, Switzerland) · 2024Review
- Article
- Identification of Novel, Potent, and Selective Compounds against Malaria Using Glideosomal-Associated Protein 50 as a Drug Target.ACS omega · 2023Article
- Article
- Intracellular persister: A stealth agent recalcitrant to antibiotics.Frontiers in cellular and infection microbiology · 2023Review
- A mathematical model analysis of the human melioidosis transmission dynamics with an asymptomatic case.Heliyon · 2022Article
- Development of Dicationic Bisguanidine-Arylfuran Derivatives as Potent Agents against Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2022Article
- Investigation of a combination therapy approach for the treatment of melioidosis.Frontiers in microbiology · 2022Article
- Article
- New Auranofin Analogs with Antibacterial Properties againstAntibiotics (Basel, Switzerland) · 2021Article
- In vitro growth inhibitory activity of Medicines for Malaria Venture pathogen box compounds against Leishmania aethiopica.BMC pharmacology & toxicology · 2021Article
- Burkholderia pseudomallei Clinical Isolates Are Highly SusceptibleAntimicrobial agents and chemotherapy · 2021Article
- Drug screening to identify compounds to act as co-therapies for the treatment of Burkholderia species.PloS one · 2021Article
- Safer In Vitro Drug Screening Models for Melioidosis Therapy Development.The American journal of tropical medicine and hygiene · 2020Article
- Predicting toxins found in toxin-antitoxin systems with a role in host-induced Burkholderia pseudomallei persistence.Scientific reports · 2020Article
- Emerging role of biologics for the treatment of melioidosis and glanders.Expert opinion on biological therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.